activity
20182023
most citedHow to design a MAMS-ROCI (aka DURATIONS) randomised trial: the REFINE-Lung case study

3 citations · 3 across the 5 of their papers we have counts for

collaborators

5 papers

stat.AP2023★ 3 cited

How to design a MAMS-ROCI (aka DURATIONS) randomised trial: the REFINE-Lung case study

Matteo Quartagno, Ehsan Ghorani, Tim P Morris +2

Background. The DURATIONS design has been recently proposed as a practical alternative to a standard two-arm non-inferiority design when the goal is to optimise some continuous asp…

stat.AP2022

Improving clinical trial interpretation with ACCEPT analyses

Michelle N. Clements, Ian R. White, Andrew J. Copas +7

Effective decision making from randomised controlled clinical trials relies on robust interpretation of the numerical results. However, the language we use to describe clinical tri…

stat.ME2020

The DURATIONS randomised trial design: estimation targets, analysis methods and operating characteristics

Matteo Quartagno, James R. Carpenter, A. Sarah Walker +2

Background. Designing trials to reduce treatment duration is important in several therapeutic areas, including TB and antibiotics. We recently proposed a new randomised trial desig…

stat.ME2019

Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation

Matteo Quartagno, A. Sarah Walker, Abdel G. Babiker +4

Background. Non-inferiority (NI) trials are increasingly used to evaluate new treatments expected to have secondary advantages over standard of care, but similar efficacy on the pr…

stat.ME2018

Re-thinking non-inferiority: a practical trial design for optimising treatment duration

Matteo Quartagno, A. Sarah Walker, James R. Carpenter +2

Background: trials to identify the minimal effective treatment duration are needed in different therapeutic areas, including bacterial infections, TB and Hepatitis--C. However, sta…